alexa Surrogate markers of efficacy for medical treatment of viral hepatitis


Journal of Antivirals & Antiretrovirals

Author(s): Block TM

Abstract Share this page

As a chronic illness, hepatitis presents a challenge for clinical research, regulatory bodies, and clinicians treating patients - how can one adequately assess the effectiveness of antiviral therapy after years or decades of undiagnosed infection? Because the outcome of infection with hepatitis B or C (HBV, HCV) may follow years or decades of infection, the clinical benefit of a therapeutic may not be recognized during the short time frames of most human clinical trials. This is in clear contrast to many other therapeutics, where the outcome and efficacy can be evaluated in few weeks or months. In HBV and HCV, it is impractical to wait until the disease has abated to determine a drug's benefit, so surrogate markers that can predict disease outcome are essential to developing effective therapies. This review will highlight the ability of surrogate markers to detect early disease and to evaluate the effectiveness of HBV and HCV therapies.

  • To read the full article Visit
  • DOI:
  • Subscription
This article was published in Biotechnol Healthc and referenced in Journal of Antivirals & Antiretrovirals

Relevant Expert PPTs

Recommended Conferences

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version